AC
Act Capital Management, LLC
13F filer · CIK 0001442273Reported Jul 29, 2026
Net buyer this quarter
13F portfolio value$153MU.S. long equity reported on 13F
Positions6220 new · 14 closed
Net flow last quarter+$5.6MBuys minus sells
Top 10 positions weight66.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 29, 202662 positions | |||||
| $16.7M | 10.93% | 0.15% | -25.6% | Q2 2021 | |
| $13.8M | 9.01% | 0.16% | +0.8% | Q2 2021 | |
| $12.9M | 8.44% | 0.12% | +36.8% | Q4 2025 | |
| $12.4M | 8.12% | 0.00% | Not reported | Q3 2021 | |
| $10.7M | 7.01% | 0.00% | +12.1% | Q2 2022 | |
| $8.97M | 5.86% | 0.08% | +33.5% | Q2 2021 | |
| $8.16M | 5.33% | 0.18% | Not reported | Q2 2021 | |
| $6.5M | 4.25% | 0.13% | -32.2% | Q4 2025 | |
| $6.23M | 4.07% | 0.44% | +26.0% | Q2 2021 | |
| $4.54M | 2.97% | 0.00% | New | Q2 2026 | |
| $4.05M | 2.64% | 0.04% | -26.4% | Q4 2025 | |
| $3.87M | 2.53% | Not reported | New | Q2 2026 | |
| $3.44M | 2.25% | 0.16% | New | Q2 2026 | |
| $3.07M | 2.01% | 0.00% | -60.9% | Q2 2021 | |
| $2.95M | 1.93% | 0.15% | +79.3% | Q4 2025 | |
| $2.9M | 1.89% | 0.05% | +43.3% | Q1 2026 | |
| $2.54M | 1.66% | 0.00% | Not reported | Q2 2022 | |
| $2.27M | 1.48% | 0.00% | +66.7% | Q4 2025 | |
| $2.04M | 1.34% | 0.00% | -15.6% | Q1 2026 | |
| $1.88M | 1.23% | 0.00% | New | Q2 2026 | |
| $1.45M | 0.95% | Not reported | -70.4% | Q1 2026 | |
| $1.37M | 0.90% | 0.04% | New | Q2 2026 | |
| $1.24M | 0.81% | Not reported | New | Q2 2026 | |
| $1.18M | 0.77% | 0.02% | New | Q2 2026 | |
| $1.09M | 0.71% | 0.00% | New | Q2 2026 | |
| $975K | 0.64% | 0.10% | +20.3% | Q4 2025 | |
| $904K | 0.59% | 0.01% | Not reported | Q4 2025 | |
| $889K | 0.58% | 0.01% | -76.8% | Q1 2026 | |
| $856K | 0.56% | 0.00% | Not reported | Q4 2021 | |
| $847K | 0.55% | 0.04% | +55.6% | Q1 2026 | |
| $809K | 0.53% | 0.12% | +20.5% | Q4 2025 | |
| $758K | 0.50% | 0.03% | New | Q2 2026 | |
| $701K | 0.46% | 0.01% | Not reported | Q4 2025 | |
| $655K | 0.43% | 0.04% | Not reported | Q4 2021 | |
| $643K | 0.42% | 0.18% | +19.4% | Q4 2025 | |
| $642K | 0.42% | 0.00% | New | Q2 2026 | |
| $567K | 0.37% | 0.00% | New | Q2 2026 | |
| $487K | 0.32% | 0.01% | Not reported | Q4 2025 | |
| $442K | 0.29% | 0.01% | Not reported | Q4 2025 | |
| $442K | 0.29% | 0.02% | -11.1% | Q1 2026 | |
| $428K | 0.28% | 0.01% | New | Q2 2026 | |
| $425K | 0.28% | 0.02% | +93.6% | Q1 2026 | |
| $403K | 0.26% | 0.03% | New | Q2 2026 | |
| $372K | 0.24% | 0.24% | Not reported | Q4 2025 | |
| $356K | 0.23% | 0.07% | +33.3% | Q4 2025 | |
| $353K | 0.23% | 0.01% | New | Q2 2026 | |
| $333K | 0.22% | 0.01% | New | Q2 2026 | |
| $330K | 0.22% | 0.00% | -44.4% | Q4 2025 | |
| $326K | 0.21% | Not reported | -40.0% | Q4 2025 | |
| $311K | 0.20% | Not reported | New | Q2 2026 | |
| Q1 2026Reported May 8, 202656 positions | |||||
| $15.6M | 12.28% | 0.21% | 0.0% | Q2 2021 | |
| $15.5M | 12.20% | 0.00% | -4.5% | Q3 2021 | |
| $11.9M | 9.33% | 0.00% | -15.2% | Q2 2022 | |
| $10.5M | 8.22% | 0.19% | +44.6% | Q4 2025 | |
| $8.27M | 6.50% | 0.16% | -7.4% | Q2 2021 | |
| $7.89M | 6.20% | 0.09% | +11.0% | Q4 2025 | |
| $6.87M | 5.40% | 0.00% | +34.2% | Q2 2021 | |
| $6.81M | 5.35% | 0.18% | +1.6% | Q2 2021 | |
| $5.17M | 4.07% | 0.06% | +10.0% | Q2 2021 | |
| $5.1M | 4.01% | 0.35% | +38.5% | Q2 2021 | |
| $4.25M | 3.34% | 0.05% | Not reported | Q4 2025 | |
| $3.84M | 3.02% | Not reported | New | Q1 2026 | |
| $2.57M | 2.02% | 0.00% | Not reported | Q2 2022 | |
| $2.26M | 1.78% | 0.00% | New | Q1 2026 | |
| $2.19M | 1.72% | 0.03% | New | Q1 2026 | |
| $1.95M | 1.53% | 0.03% | New | Q1 2026 | |
| $1.24M | 0.98% | 0.08% | -52.5% | Q4 2025 | |
| $1.04M | 0.82% | 0.11% | Not reported | Q2 2021 | |
| $870K | 0.68% | 0.01% | +285.7% | Q4 2025 | |
| $813K | 0.64% | 0.01% | -55.2% | Q4 2025 | |
| $699K | 0.55% | Not reported | New | Q1 2026 | |
| $632K | 0.50% | 0.00% | New | Q1 2026 | |
| $610K | 0.48% | 0.00% | -65.4% | Q4 2025 | |
| $608K | 0.48% | 0.01% | -26.6% | Q4 2025 | |
| $601K | 0.47% | 0.08% | Not reported | Q4 2025 | |
| $576K | 0.45% | 0.04% | Not reported | Q4 2021 | |
| $572K | 0.45% | Not reported | New | Q1 2026 | |
| $559K | 0.44% | 0.01% | -50.0% | Q4 2025 | |
| $555K | 0.44% | Not reported | +6.4% | Q4 2025 | |
| $531K | 0.42% | 0.01% | -10.0% | Q4 2025 | |
| $514K | 0.40% | 0.03% | +166.7% | Q4 2025 | |
| $507K | 0.40% | 0.00% | New | Q1 2026 | |
| $488K | 0.38% | 0.00% | Not reported | Q2 2021 | |
| $470K | 0.37% | 0.07% | Not reported | Q4 2025 | |
| $469K | 0.37% | 0.11% | -32.1% | Q4 2025 | |
| $451K | 0.35% | 0.15% | +71.7% | Q4 2025 | |
| $373K | 0.29% | 0.03% | -53.3% | Q4 2025 | |
| $370K | 0.29% | 0.03% | New | Q1 2026 | |
| $339K | 0.27% | 0.01% | New | Q1 2026 | |
| $283K | 0.22% | 0.24% | Not reported | Q4 2025 | |
| $269K | 0.21% | 0.02% | New | Q1 2026 | |
| $268K | 0.21% | 1500.00% | New | Q1 2026 | |
| $259K | 0.20% | 0.05% | +19.5% | Q4 2025 | |
| $243K | 0.19% | 0.02% | New | Q1 2026 | |
| $209K | 0.16% | 0.04% | Not reported | Q4 2025 | |
| $188K | 0.15% | 0.00% | New | Q1 2026 | |
| $152K | 0.12% | 0.01% | +233.3% | Q4 2025 | |
| $130K | 0.10% | 0.02% | New | Q1 2026 | |
| ETESPREsperion Therapeutics, Inc. | $130K | 0.10% | 0.02% | Not reported | Q4 2025 |
| $125K | 0.10% | 0.01% | Not reported | Q4 2025 | |
| Q4 2025Reported Feb 17, 202656 positions | |||||
| $14.9M | 12.06% | 0.21% | +3.8% | Q2 2021 | |
| $12M | 9.67% | 0.00% | +248.9% | Q3 2021 | |
| $9.93M | 8.03% | 0.00% | +1.1% | Q2 2022 | |
| $8.62M | 6.97% | 0.08% | New | Q4 2025 | |
| $8.02M | 6.48% | 0.17% | Not reported | Q2 2021 | |
| $7.25M | 5.86% | 0.18% | Not reported | Q2 2021 | |
| $6.33M | 5.11% | 0.13% | New | Q4 2025 | |
| $5.68M | 4.59% | 0.00% | Not reported | Q2 2021 | |
| $5.47M | 4.42% | 0.18% | New | Q4 2025 | |
| $4.98M | 4.03% | 0.05% | -32.1% | Q2 2021 | |
| $4.1M | 3.31% | 0.05% | New | Q4 2025 | |
| $2.68M | 2.17% | 0.02% | New | Q4 2025 | |
| $2.35M | 1.90% | 0.02% | New | Q4 2025 | |
| $2.35M | 1.90% | Not reported | New | Q4 2025 | |
| $2.32M | 1.88% | 0.00% | New | Q4 2025 | |
| $2.19M | 1.77% | 0.00% | +4.2% | Q2 2022 | |
| $2.16M | 1.75% | 0.25% | Not reported | Q2 2021 | |
| $1.34M | 1.08% | 0.07% | New | Q4 2025 | |
| $1.33M | 1.08% | 0.00% | New | Q4 2025 | |
| $1.28M | 1.04% | 0.11% | -75.1% | Q2 2021 | |
| $1.19M | 0.96% | 0.16% | New | Q4 2025 | |
| $1.13M | 0.91% | 0.01% | New | Q4 2025 | |
| $1.06M | 0.86% | 0.02% | New | Q4 2025 | |
| $1.05M | 0.85% | 0.00% | New | Q4 2025 | |
| $831K | 0.67% | 0.00% | New | Q4 2025 | |
| $806K | 0.65% | 0.00% | -73.3% | Q1 2022 | |
| $770K | 0.62% | Not reported | New | Q4 2025 | |
| $768K | 0.62% | 0.08% | New | Q4 2025 | |
| $718K | 0.58% | 0.00% | New | Q4 2025 | |
| $598K | 0.48% | 0.08% | New | Q4 2025 | |
| $529K | 0.43% | 0.01% | New | Q4 2025 | |
| ATAPGEApogee Therapeutics, Inc. | $528K | 0.43% | 0.01% | New | Q4 2025 |
| $514K | 0.42% | 0.02% | New | Q4 2025 | |
| $390K | 0.32% | 0.01% | New | Q4 2025 | |
| $353K | 0.29% | 0.09% | New | Q4 2025 | |
| $335K | 0.27% | 0.24% | New | Q4 2025 | |
| $293K | 0.24% | 0.01% | New | Q4 2025 | |
| $236K | 0.19% | 0.04% | New | Q4 2025 | |
| $231K | 0.19% | 0.03% | New | Q4 2025 | |
| $212K | 0.17% | 0.07% | Not reported | Q2 2021 | |
| $208K | 0.17% | 0.04% | New | Q4 2025 | |
| $206K | 0.17% | 0.00% | New | Q4 2025 | |
| ETESPREsperion Therapeutics, Inc. | $176K | 0.14% | 0.02% | New | Q4 2025 |
| $151K | 0.12% | 0.01% | New | Q4 2025 | |
| DODAWNDay One Biopharmaceuticals, Inc. | $120K | 0.10% | 0.01% | New | Q4 2025 |
| $115K | 0.09% | 0.00% | New | Q4 2025 | |
| $109K | 0.09% | 0.01% | New | Q4 2025 | |
| $107K | 0.09% | 0.00% | New | Q4 2025 | |
| $86.8K | 0.07% | 0.01% | -71.4% | Q3 2021 | |
| $84.7K | 0.07% | 0.01% | Not reported | Q1 2022 | |
| Q3 2022Reported Nov 3, 202262 positions | |||||
| $15.7M | 21.69% | 0.46% | -2.7% | Q2 2021 | |
| $7.12M | 9.83% | Not reported | +43.4% | Q2 2022 | |
| $4.96M | 6.85% | 0.01% | Not reported | Q1 2022 | |
| $4.06M | 5.61% | 0.23% | -1.2% | Q2 2021 | |
| $3.65M | 5.04% | 0.10% | -18.2% | Q2 2021 | |
| $3.26M | 4.50% | 0.17% | Not reported | Q2 2021 | |
| $3.23M | 4.46% | 0.00% | +15.4% | Q3 2021 | |
| $2.94M | 4.05% | 0.19% | Not reported | Q4 2021 | |
| $2.52M | 3.48% | 4.24% | Not reported | Q4 2021 | |
| CBCLSDClearside Biomedical, Inc. | $2.48M | 3.43% | 3.65% | -4.0% | Q2 2021 |
| VEVTLEVital Energy, Inc. | $2.13M | 2.94% | 0.20% | +164.8% | Q2 2022 |
| $1.78M | 2.46% | 0.45% | -46.9% | Q2 2021 | |
| EBEIGREiger Biopharmaceuticals, Inc. | $1.77M | 2.44% | 0.53% | -6.0% | Q2 2021 |
| VPVRNAVerona Pharma plc | $1.47M | 2.02% | 0.02% | New | Q3 2022 |
| $1.41M | 1.95% | 0.00% | Not reported | Q2 2022 | |
| $1.27M | 1.75% | 0.01% | +162.5% | Q4 2021 | |
| MSMYOVMyovant Sciences Ltd. | $1.08M | 1.49% | 0.06% | -7.7% | Q2 2021 |
| $937K | 1.29% | 0.84% | -5.9% | Q3 2021 | |
| $853K | 1.18% | 3.72% | Not reported | Q2 2021 | |
| $761K | 1.05% | 0.01% | +141.1% | Q2 2022 | |
| CNCMBMFCambium Networks Corp | $582K | 0.80% | 0.13% | New | Q3 2022 |
| $522K | 0.72% | 0.04% | Not reported | Q2 2021 | |
| $504K | 0.70% | 52.41% | -30.0% | Q3 2021 | |
| $469K | 0.65% | 0.46% | Not reported | Q2 2021 | |
| IICADIcad Inc | $431K | 0.59% | 0.81% | Not reported | Q2 2021 |
| $398K | 0.55% | 0.00% | -52.5% | Q2 2021 | |
| $391K | 0.54% | 0.05% | Not reported | Q2 2022 | |
| DDENDenbury Inc | $345K | 0.48% | Not reported | New | Q3 2022 |
| $340K | 0.47% | Not reported | -29.0% | Q3 2021 | |
| $330K | 0.46% | Not reported | New | Q3 2022 | |
| $284K | 0.39% | 0.04% | -27.3% | Q2 2021 | |
| $241K | 0.33% | Not reported | Not reported | Q2 2021 | |
| $236K | 0.33% | 0.00% | New | Q3 2022 | |
| $234K | 0.32% | Not reported | New | Q3 2022 | |
| $233K | 0.32% | Not reported | Not reported | Q2 2021 | |
| $186K | 0.26% | 0.28% | Not reported | Q2 2021 | |
| SOSURFSurface Oncology, Inc. | $177K | 0.24% | 0.28% | Not reported | Q2 2021 |
| $170K | 0.23% | 0.00% | New | Q3 2022 | |
| $145K | 0.20% | 0.00% | -60.0% | Q4 2021 | |
| $142K | 0.20% | 0.01% | Not reported | Q2 2021 | |
| $131K | 0.18% | 0.42% | Not reported | Q2 2021 | |
| MTMDNAFMedicenna Therapeutics Corp. | $124K | 0.17% | 0.27% | Not reported | Q2 2021 |
| GBGRTSGritstone bio, Inc. | $122K | 0.17% | 0.06% | Not reported | Q3 2021 |
| ATADAPYAdaptimmune Therapeutics PLC | $97K | 0.13% | 0.01% | Not reported | Q3 2021 |
| $95K | 0.13% | 0.41% | Not reported | Q3 2021 | |
| $73K | 0.10% | 0.36% | 0.0% | Q2 2021 | |
| $64K | 0.09% | 0.08% | Not reported | Q2 2021 | |
| SDSDPISuperior Drilling Products, Inc. | $54K | 0.07% | 0.27% | Not reported | Q2 2021 |
| $48K | 0.07% | 0.08% | Not reported | Q2 2021 | |
| TPTCONTRACON Pharmaceuticals, Inc. | $48K | 0.07% | 0.13% | Not reported | Q2 2021 |
Premium opens every quarter this fund has filed